R. Charles Coombes

53.3k total citations · 4 hit papers
614 papers, 33.0k citations indexed

About

R. Charles Coombes is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, R. Charles Coombes has authored 614 papers receiving a total of 33.0k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Oncology, 218 papers in Molecular Biology and 205 papers in Genetics. Recurrent topics in R. Charles Coombes's work include Estrogen and related hormone effects (182 papers), Breast Cancer Treatment Studies (72 papers) and Cancer Cells and Metastasis (59 papers). R. Charles Coombes is often cited by papers focused on Estrogen and related hormone effects (182 papers), Breast Cancer Treatment Studies (72 papers) and Cancer Cells and Metastasis (59 papers). R. Charles Coombes collaborates with scholars based in United Kingdom, United States and Belgium. R. Charles Coombes's co-authors include Simak Ali, David M. Vigushin, Mitch Dowsett, J.-C. Gazet, U Berger, Eric W.‐F. Lam, Susan Cleator, Justin Stebbing, W. Heller and Paul Pace and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Physical Review Letters.

In The Last Decade

R. Charles Coombes

609 papers receiving 32.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

2011 1.5k citations R. Charles Coombes et al. profile →
Triple-negative breast cancer: therapeutic options

2007 719 citations Susan Cleator, W. Heller et al. The Lancet Oncology profile →
Endocrine-responsive breast cancer and strategies for combating resistance

2002 696 citations Simak Ali, R. Charles Coombes profile →
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

2009 581 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Charles Coombes United Kingdom	97	13.6k	13.6k	9.1k	8.8k	4.4k	614	33.0k
Nancy E. Davidson United States	99	20.5k 1.5×	17.6k 1.3×	12.3k 1.3×	7.8k 0.9×	5.7k 1.3×	398	41.0k
Anthony Howell United Kingdom	112	21.3k 1.6×	12.4k 0.9×	15.1k 1.7×	14.7k 1.7×	6.6k 1.5×	684	42.9k
William McGuire United States	94	15.8k 1.2×	12.5k 0.9×	7.9k 0.9×	11.3k 1.3×	6.2k 1.4×	472	41.7k
Marc E. Lippman United States	97	12.7k 0.9×	12.5k 0.9×	7.0k 0.8×	10.2k 1.2×	2.2k 0.5×	413	30.2k
Douglas F. Easton United Kingdom	96	8.8k 0.6×	12.8k 0.9×	8.0k 0.9×	16.9k 1.9×	3.4k 0.8×	358	33.9k
James N. Ingle United States	74	13.9k 1.0×	5.6k 0.4×	9.4k 1.0×	7.9k 0.9×	4.0k 0.9×	365	23.6k
Steven A. Narod Canada	99	14.1k 1.0×	12.1k 0.9×	12.5k 1.4×	20.0k 2.3×	5.1k 1.2×	703	41.1k
Waun Ki Hong United States	98	12.7k 0.9×	16.8k 1.2×	5.5k 0.6×	3.8k 0.4×	8.1k 1.8×	512	34.0k
Edith A. Perez United States	79	20.7k 1.5×	6.6k 0.5×	11.1k 1.2×	4.4k 0.5×	5.8k 1.3×	400	30.1k
Eleftherios P. Diamandis Canada	103	9.7k 0.7×	17.2k 1.3×	6.2k 0.7×	2.9k 0.3×	5.8k 1.3×	940	44.5k

Countries citing papers authored by R. Charles Coombes

Since Specialization

Citations

This map shows the geographic impact of R. Charles Coombes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Charles Coombes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Charles Coombes more than expected).

Fields of papers citing papers by R. Charles Coombes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Charles Coombes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Charles Coombes. The network helps show where R. Charles Coombes may publish in the future.

Co-authorship network of co-authors of R. Charles Coombes

This figure shows the co-authorship network connecting the top 25 collaborators of R. Charles Coombes. A scholar is included among the top collaborators of R. Charles Coombes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Charles Coombes. R. Charles Coombes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coombes, R. Charles, William E. Hart, Darius Francescatti, et al.. (2024). Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study. Breast Cancer Research and Treatment. 205(2). 349–358. 3 indexed citations

Patel, Hetal, Manikandan Periyasamy, Georgina P. Sava, et al.. (2018). ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Molecular Cancer Therapeutics. 17(6). 1156–1166. 111 indexed citations

Shaw, Jacqui, David S. Guttery, Allison Hills, et al.. (2016). Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clinical Cancer Research. 23(1). 88–96. 171 indexed citations

Zwart, Wilbert, Koen D. Flach, Tarek M.A. Abdel-Fatah, et al.. (2015). SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. Clinical Cancer Research. 22(2). 479–491. 14 indexed citations

Benzonana, Laura L., Nicholas J. S. Perry, Helena Watts, et al.. (2013). Isoflurane, a Commonly Used Volatile Anesthetic, Enhances Renal Cancer Growth and Malignant Potential via the Hypoxia-inducible Factor Cellular Signaling Pathway In Vitro. Anesthesiology. 119(3). 593–605. 166 indexed citations

Contractor, Kaiyumars, Laura Kenny, Justin Stebbing, et al.. (2011). [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel. Clinical Cancer Research. 17(24). 7664–7672. 68 indexed citations

Page, Karen, Natasha Hava, Brian Ward, et al.. (2011). Detection of HER2 amplification in circulating free DNA in patients with breast cancer. British Journal of Cancer. 104(8). 1342–1348. 68 indexed citations

Shaw, Jacqui, James A. L. Brown, R. Charles Coombes, et al.. (2011). Circulating Tumor Cells and Plasma DNA Analysis in Patients with Indeterminate Early or Metastatic Breast Cancer. Biomarkers in Medicine. 5(1). 87–91. 27 indexed citations

Kenny, Laura, Kaiyumars Contractor, Rainer Hinz, et al.. (2010). Reproducibility of [11C]Choline-Positron Emission Tomography and Effect of Trastuzumab. Clinical Cancer Research. 16(16). 4236–4245. 42 indexed citations

10.

Peck, Barrie, Chun‐Yuan Chen, Ka-Kei Ho, et al.. (2010). SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2. Molecular Cancer Therapeutics. 9(4). 844–855. 371 indexed citations

11.

Kwok, Jimmy M-M., Barrie Peck, Lara J. Monteiro, et al.. (2010). FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells. Molecular Cancer Research. 8(1). 24–34. 167 indexed citations

12.

McGovern, Ursula, Richard E. Francis, Barrie Peck, et al.. (2009). Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular Cancer Therapeutics. 8(3). 582–591. 115 indexed citations

13.

Horlock, Claire, B. Stott, Paul J. Dyson, et al.. (2009). The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. British Journal of Cancer. 100(7). 1061–1067. 81 indexed citations

14.

Dowsett, Mitch, Jack Cuzick, J. N. Ingle, et al.. (2009). Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. Journal of Clinical Oncology. 28(3). 509–518. 581 indexed citations breakdown →

15.

Castellano, Leandro, Georgios Giamas, Jimmy Jacob, et al.. (2009). The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response. Proceedings of the National Academy of Sciences. 106(37). 15732–15737. 280 indexed citations

16.

Cleator, Susan, W. Heller, & R. Charles Coombes. (2007). Triple-negative breast cancer: therapeutic options. The Lancet Oncology. 8(3). 235–244. 719 indexed citations breakdown →

17.

Poon, Grace K., David M. Vigushin, Leslie J. Griggs, et al.. (1996). IDENTIFICATION AND CHARACTERIZATION OF LIMONENE METABOLITES IN PATIENTS WITH ADVANCED CANCER BY LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY. Drug Metabolism and Disposition. 24(5). 565–571. 39 indexed citations

18.

Mansi, Janine, Helena Earl, T.J. Powles, & R. Charles Coombes. (1988). Tests for detecting recurrent disease in the follow-up of patients with breast cancer. Breast Cancer Research and Treatment. 11(3). 249–254. 16 indexed citations

19.

Vincent, Mark, H.M. Clink, R. Charles Coombes, et al.. (1985). Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer.. BMJ. 291(6488). 105.2–106. 14 indexed citations

20.

Gazet, J C, Richard Rainsbury, H.T. Ford, T.J. Powles, & R. Charles Coombes. (1985). Survey of treatment of primary breast cancer in Great Britain.. BMJ. 290(6484). 1793–1795. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact